INCYIncyte CorporationRunning, no new patients
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 82 (final count)
- Started
- Dec 23, 2022
- Main results expected
- Mar 30, 2026
- Fully finished
- Apr 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR)
Measured over: Approximately 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05429268 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC